Table 5 Associations of 1-year INT changes of single acylcarnitines(Dif) and combined indexes with eGFR Change(T2/T1)(Log2 transformed)
From: Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy
Log2(eGFR Change),INT(CarDif) | Adjust T1GFR + T1Carnitine + Age + Sex | ||
|---|---|---|---|
β | SE | P | |
Free carnitine (C0) | −0.49 | 0.13 | 0.007492944 |
Acetylcarnitine (C2) | −0.34 | 0.13 | 0.06034281 |
Butyrylcarnitine (C4) | −0.43 | 0.12 | 0.008221232 |
semi Tiglyl-carnitine (C5:1) | −0.12 | 0.12 | 0.599218799 |
Valerylcarnitine (C5) | −0.37 | 0.14 | 0.042476427 |
semi Octanenoylcarnitine (C8:1) | −0.29 | 0.11 | 0.042476427 |
Octanoylcarnitine (C8) | 0.02 | 0.13 | 0.981932317 |
Malonylcarnitine (C3DC) | −0.37 | 0.1 | 0.008221232 |
C10:1 | −0.11 | 0.14 | 0.70587576 |
Decanoylcarnitine (C10) | 0.02 | 0.13 | 0.981932317 |
C5DC | −0.21 | 0.09 | 0.087001606 |
semi Dodecenoylcarnitine (C12:1) | −0.17 | 0.12 | 0.42430295 |
Dodecanoylcarnitine (C12) | −0.01 | 0.13 | 0.981932317 |
semi 3-Hydroxydodecanoylcarnitne (C12OH) | −0.15 | 0.12 | 0.513747479 |
C14:1 | 0 | 0.14 | 0.981932317 |
Myristoylcarnitine (C14) | 0.01 | 0.12 | 0.981932317 |
semi (C16:2) | −0.17 | 0.12 | 0.42430295 |
semi Palmitoleylcarnitine (C16:1) | −0.16 | 0.12 | 0.426208624 |
Palmitoylcarnitine (C16) | −0.11 | 0.12 | 0.645845281 |
semi Sebacylcarnitine (C10DC) | −0.09 | 0.13 | 0.732411215 |
semi Linoleylcarnitine(C18:2) | 0.05 | 0.12 | 0.934179803 |
semi Oleylcarnitine (C18:1) | −0.03 | 0.12 | 0.981932317 |
semi Stearoylcarnitine (C18) | −0.07 | 0.13 | 0.870583478 |
semi C12DC | −0.11 | 0.13 | 0.70587576 |
semi 3-Hydroxylinoleyl(C18:2OH) | −0.02 | 0.14 | 0.981932317 |
semi Arachidoylcarnitine (C20) | −0.19 | 0.13 | 0.42430295 |